Rutika Mehta, MD
Hematology & Oncology · New York, NYNPI 1437443181
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $96,554 of the $137,485 with a category attached, or 70.2%. It is spread thinly across 32 manufacturers, the largest accounting for just 19.0%. 2025 is the largest year on record at $34,111, 8.2 times the $4,139 reported in 2019. Among hematology & oncology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 161 payments — averaging $853.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$26K
- E.r. Squibb & Sons, L.L.C.$16K
- Amgen$12K
- Seagen Inc.$10K
- Astellas Pharma Global Development$9K
- Jazz Pharmaceuticals Inc.$9K
- plus $56K from 26 others
Across 62 payments — averaging $4121.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$122K
- Merck$59K
- Karyopharm Therapeutics Inc.$47K
- AstraZeneca$26K
- Daiichi Sankyo Inc.$2K
What the payments were for
- Consulting fees$96,55470%
- Speaking & faculty fees$29,58322%
- Travel & lodging$6,6425%
- Food & beverage$4,6293%
- Education$770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 11 | $26,109 |
| E.r. Squibb & Sons, L.L.C. | 20 | $15,999 |
| Amgen | 4 | $11,903 |
| Seagen Inc. | 9 | $10,485 |
| Astellas Pharma Global Development | 14 | $8,771 |
| Jazz Pharmaceuticals Inc. | 5 | $8,625 |
| Taiho Oncology, Inc. | 10 | $8,344 |
| AstraZeneca | 7 | $6,825 |
| Beone Medicines USA, Inc. | 9 | $5,917 |
| GSK | 3 | $4,775 |
| Merck | 7 | $4,697 |
| Daiichi Sankyo Inc. | 4 | $4,234 |
| Exelixis Inc. | 7 | $3,905 |
| Astellas Pharma US Inc | 7 | $3,068 |
| Beigene USA, Inc. | 2 | $2,700 |
| Gilead | 1 | $2,540 |
| Eisai Inc. | 2 | $2,447 |
| Legend Biotech USA Inc. | 1 | $2,190 |
| Novartis | 5 | $1,868 |
| Ipsen Biopharmaceuticals, Inc | 4 | $438 |
| Array Biopharma Inc | 11 | $336 |
| Foundation Medicine, Inc. | 2 | $286 |
| Bayer | 4 | $283 |
| Genentech USA, Inc. | 2 | $271 |
| Pfizer | 2 | $110 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $93 |
| Sirtex Medical Inc | 1 | $89 |
| Immunitybio, Inc. | 1 | $59 |
| AbbVie | 2 | $45 |
| Incyte Corporation | 1 | $30 |
| Tersera Therapeutics LLC | 1 | $27 |
| Smith+Nephew | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vyloy$10,311
- TUKYSA$10,290
- ZIIHERA$8,454
- TEVIMBRA$5,025
- OPDIVO$4,020
- JEMPERLI$2,600
- LENVIMA$2,370
- Enhertu$2,359
- IMFINZI$2,185
- Lonsurf$1,500
- CYRAMZA$1,350
- SOMATULINE DEPOT$414
- ONIVYDE$414
- FOUNDATIONONE CDX$286
- TECENTRIQ$146
- ZANIDATAMAB$146
- Avastin$125
- FOUNDATIONONE$116
- FOUNDATIONONE HEME$116
- FOUNDATIONFOCUS$116
How this compares
$137,485 in reported general payments places this provider in the 90th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 28 | $1,048 |
| Prochlorperazine Maleate | 23 | $692 |
| Tramadol Hcl | 14 | $320 |
| Pantoprazole Sodium | 26 | $141 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in New York
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Ross LevineNew York$968K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
- Jeffrey LaurenceNew York$640K
- John AllanNew York$580K
- Ilan ShapiraNew York$475K
- John MascarenhasNew York$456K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.